300199 翰宇药业
已收盘 12-05 15:00:00
资讯
新帖
简况
翰宇药业：多肽原料药总产能可达5吨以上
证券之星 · 12-03
翰宇药业：多肽原料药总产能可达5吨以上
医药“一哥”高管，空降翰宇药业
蓝鲸财经 · 11-28
医药“一哥”高管，空降翰宇药业
翰宇药业（300199）披露召开2025年第四次临时股东大会通知，11月17日股价下跌3.29%
证券之星 · 11-17
翰宇药业（300199）披露召开2025年第四次临时股东大会通知，11月17日股价下跌3.29%
翰宇药业：聚焦多肽制剂、原料药、小核酸与CRDMO四大业务板块
证券之星 · 11-13
翰宇药业：聚焦多肽制剂、原料药、小核酸与CRDMO四大业务板块
翰宇药业（300199）披露公司向高新投集团及子公司融资议案获通过，11月06日股价下跌2.16%
证券之星 · 11-06
翰宇药业（300199）披露公司向高新投集团及子公司融资议案获通过，11月06日股价下跌2.16%
翰宇药业（300199）2025年三季报简析：营收净利润同比双双增长，短期债务压力上升
证券之星 · 10-31
翰宇药业（300199）2025年三季报简析：营收净利润同比双双增长，短期债务压力上升
翰宇药业：司美格鲁肽III期临床进入收尾阶段
证券之星 · 10-30
翰宇药业：司美格鲁肽III期临床进入收尾阶段
翰宇药业（300199）披露拟向深圳市高新投集团及子公司融资议案，10月21日股价上涨0.99%
证券之星 · 10-21
翰宇药业（300199）披露拟向深圳市高新投集团及子公司融资议案，10月21日股价上涨0.99%
翰宇药业拟不超9.7亿定增 扣非亏7年实控人持股9成质押
中金财经 · 09-26
翰宇药业拟不超9.7亿定增 扣非亏7年实控人持股9成质押
翰宇药业最新公告：拟定增募资不超过9.68亿元 用于司美格鲁肽研发项目等
证券之星 · 09-25
翰宇药业最新公告：拟定增募资不超过9.68亿元 用于司美格鲁肽研发项目等
翰宇药业称计划通过股份私募筹集最多9.68亿元资金用于项目投资和补充资本
美股速递 · 09-25
翰宇药业称计划通过股份私募筹集最多9.68亿元资金用于项目投资和补充资本
股市必读：翰宇药业(300199)股东户数6.3万户，较上期增加9.95%
证券之星 · 08-25
股市必读：翰宇药业(300199)股东户数6.3万户，较上期增加9.95%
翰宇药业（300199）2025年中报简析：营收净利润同比双双增长，短期债务压力上升
证券之星 · 08-23
翰宇药业（300199）2025年中报简析：营收净利润同比双双增长，短期债务压力上升
翰宇药业披露4笔对外担保，被担保公司2家
证券之星 · 08-22
翰宇药业披露4笔对外担保，被担保公司2家
图解翰宇药业中报：第二季度单季净利润同比增长1919.66%
证券之星 · 08-21
图解翰宇药业中报：第二季度单季净利润同比增长1919.66%
翰宇药业最新公告：醋酸阿托西班注射液获得越南药品上市许可
证券之星 · 08-21
翰宇药业最新公告：醋酸阿托西班注射液获得越南药品上市许可
翰宇药业与中国科学院过程工程研究所达成战略合作
市场资讯 · 08-20
翰宇药业与中国科学院过程工程研究所达成战略合作
翰宇药业股价下跌2.17% 与三生蔓迪签署减重药物商业化协议
金融界 · 08-20
翰宇药业股价下跌2.17% 与三生蔓迪签署减重药物商业化协议
翰宇药业最新公告：与三生蔓迪签署司美格鲁肽注射液合作协议补充协议
证券之星 · 08-19
翰宇药业最新公告：与三生蔓迪签署司美格鲁肽注射液合作协议补充协议
翰宇药业最新公告：副总裁张宝乐因个人原因辞职
证券之星 · 08-15
翰宇药业最新公告：副总裁张宝乐因个人原因辞职
加载更多
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司的主营业务是多肽药物研发、生产和销售。公司的主要产品是多肽制剂、多肽原料药、小核酸、CDMO/CMO。公司共获得国内专利授权298件，其中发明专利291件；翰宇药业（武汉）获得国内专利授权18件；成纪药业共获得国内专利授权115件。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":18.9,"timestamp":1764918207000,"preClose":18.35,"halted":0,"volume":24872872,"delay":0,"changeRate":0.03,"floatShares":746000000,"shares":883000000,"eps":-0.0765,"marketStatus":"已收盘","change":0.55,"latestTime":"12-05 15:00:00","open":18.3,"high":18.95,"low":18.13,"amount":463000000,"amplitude":0.0447,"askPrice":18.9,"askSize":2077,"bidPrice":18.89,"bidSize":1059,"shortable":0,"etf":0,"ttmEps":-0.0765,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":18.35,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":20.19,"lowLimit":16.52,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"isCdr":false,"pbRate":24.97,"roa":"--","roe":"11.62%","epsLYR":-0.2,"committee":-0.417808,"marketValue":16693000000,"turnoverRate":0.0334,"status":0,"floatMarketCap":14094000000},"requestUrl":"/m/hq/s/300199","defaultTab":"news","newsList":[{"id":"2588915530","title":"翰宇药业：多肽原料药总产能可达5吨以上","url":"https://stock-news.laohu8.com/highlight/detail?id=2588915530","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588915530?lang=zh_cn&edition=full","pubTime":"2025-12-03 11:48","pubTimestamp":1764733699,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好，关于替尔泊肽原料药明年的预计产能是？谢谢翰宇药业回复：您好，目前公司多肽原料药总产能可达5吨以上，具体产品的年度排产计划将综合市场及合作需求等动态制定，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300013704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0188","BK0077","BK0239","BK0028","BK0070"],"gpt_icon":0},{"id":"2586206136","title":"医药“一哥”高管，空降翰宇药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2586206136","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586206136?lang=zh_cn&edition=full","pubTime":"2025-11-28 14:45","pubTimestamp":1764312358,"startTime":"0","endTime":"0","summary":"事后，涉案原高管被判刑，公司计提相关费用，对利润产生显著冲击。一个偶然的契机，其发现国内多肽赛道有巨大成长空间，由此找到医药专家袁建成，共同组建翰宇药业的前身。2022年，袁建成挪用公司资金案彻底浮出水面，其本人于2024年被终审判刑。其中，司美格鲁肽因受技术保护期限，国产厂家仍未获批上市，但进度较快的华东医药早已摩拳擦掌等待专利“开闸”。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1764293051486213495","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["300199","BK1574","BK0188","09939","BK0077","BK0239","BK1161","BK0028","159938","BK0070","BK1515"],"gpt_icon":0},{"id":"2584621379","title":"翰宇药业（300199）披露召开2025年第四次临时股东大会通知，11月17日股价下跌3.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584621379","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584621379?lang=zh_cn&edition=full","pubTime":"2025-11-17 22:12","pubTimestamp":1763388778,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，翰宇药业报收于19.4元，较前一交易日下跌3.29%，最新总市值为171.35亿元。该股当日开盘19.81元，最高19.83元，最低19.4元，成交额达7.17亿元，换手率为4.93%。近日，翰宇药业发布公告称，公司将于2025年12月5日召开2025年第四次临时股东大会，会议由董事会召集，采取现场投票与网络投票相结合的方式进行。股权登记日为2025年11月28日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700036541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","300199","BK0070","BK0028"],"gpt_icon":0},{"id":"2583756063","title":"翰宇药业：聚焦多肽制剂、原料药、小核酸与CRDMO四大业务板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2583756063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583756063?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:48","pubTimestamp":1763038129,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业11月13日在投资者关系平台上答复投资者关心的问题。公司定增及三季度业绩暴雷，至始至终没有给投资者一个好的回答，顾左言右，草草敷衍，给股价造成严重影响，希望公司能正视问题，躬身自省，出台措施做好市值管理，维护投资者利益！公司一直专注于主营，聚焦多肽制剂、原料药、小核酸与CRDMO四大业务板块，不断提升自身生产经营能力，力争实现更好的盈利，为股东创造更多价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300039808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","BK0070","300199","BK0077"],"gpt_icon":0},{"id":"2581091651","title":"翰宇药业（300199）披露公司向高新投集团及子公司融资议案获通过，11月06日股价下跌2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091651","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581091651?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:11","pubTimestamp":1762438279,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，翰宇药业报收于20.83元，较前一交易日下跌2.16%，最新总市值为183.98亿元。该股当日开盘21.0元，最高21.15元，最低20.8元，成交额达8.28亿元，换手率为5.32%。本次股东大会于2025年11月6日以现场和网络投票方式召开，审议通过了《关于向深圳市高新投集团有限公司及下设子公司融资的议案》。表决结果显示，同意股份占出席会议有效表决权的99.2557%，议案获得通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0188","BK0028","BK0070","BK0077","BK0239"],"gpt_icon":0},{"id":"2579460101","title":"翰宇药业（300199）2025年三季报简析：营收净利润同比双双增长，短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579460101","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579460101?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:48","pubTimestamp":1761864495,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期翰宇药业发布2025年三季报。截至本报告期末，公司营业总收入6.83亿元，同比上升82.06%，归母净利润7135.15万元，同比上升305.0%。按单季度数据看，第三季度营业总收入1.34亿元，同比上升11.86%，第三季度归母净利润-7411.71万元，同比下降203.18%。本报告期翰宇药业短期债务压力上升，流动比率达0.37。本次财报公布的各项数据指标表现尚佳。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100009864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2579144289","title":"翰宇药业：司美格鲁肽III期临床进入收尾阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2579144289","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579144289?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:52","pubTimestamp":1761828735,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司计划何时公布司美格鲁肽三期临床测试结果？谢谢翰宇药业回复：公司司美格鲁肽注射液体重管理和和降糖适应症均已开展III期临床，所有受试者均已入组，已进行给药及随访，并进入收尾阶段，预计年内完临床试验，相关临床结果请关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0028","BK0070","BK0188","300199"],"gpt_icon":0},{"id":"2577879193","title":"翰宇药业（300199）披露拟向深圳市高新投集团及子公司融资议案，10月21日股价上涨0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577879193","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577879193?lang=zh_cn&edition=full","pubTime":"2025-10-21 22:10","pubTimestamp":1761055835,"startTime":"0","endTime":"0","summary":"截至2025年10月21日收盘，翰宇药业报收于21.45元，较前一交易日上涨0.99%，最新总市值为189.46亿元。该股当日开盘21.07元，最高21.6元，最低20.8元，成交额达8.97亿元，换手率为5.66%。近日，翰宇药业发布公告称，公司将于2025年11月6日15:30召开2025年第三次临时股东大会，会议将审议《关于向深圳市高新投集团有限公司及下设子公司融资的议案》。股东可于2025年11月3日前通过信函或传真方式登记，不接受电话登记。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100036871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300199","BK0077","BK0070","BK0239","BK0028"],"gpt_icon":0},{"id":"2570496072","title":"翰宇药业拟不超9.7亿定增 扣非亏7年实控人持股9成质押","url":"https://stock-news.laohu8.com/highlight/detail?id=2570496072","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570496072?lang=zh_cn&edition=full","pubTime":"2025-09-26 15:07","pubTimestamp":1758870421,"startTime":"0","endTime":"0","summary":"中国经济网北京9月26日讯 翰宇药业 今日股价下跌，开盘报22.38元，跌幅3.20%。 翰宇药业昨晚披露的2025年度向特定对象发行A股股票预案显示，公司本次发行募集资金总额不超过人民币96,800.00万元(含本数)，在扣除相关发行费用后的募集资金净额将全部用于以下项目：多肽药物产线及绿色智能化扩建项目、多肽片段扩产建设项目、研发实验室升级项目、司美格鲁肽研发项目和补充流动资金。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202509/26/20250926886021.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202509/26/20250926886021.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20250926/31675299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300199","BK0077","BK0028","BK0070","BK0188","BK0239"],"gpt_icon":0},{"id":"2570094527","title":"翰宇药业最新公告：拟定增募资不超过9.68亿元 用于司美格鲁肽研发项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2570094527","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570094527?lang=zh_cn&edition=full","pubTime":"2025-09-25 19:40","pubTimestamp":1758800432,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，拟向特定对象发行股票，募集资金总额不超过9.68亿元，用于多肽药物产线及绿色智能化扩建项目、多肽片段扩产建设项目、研发实验室升级项目、司美格鲁肽研发项目及补充流动资金。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092500030586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0028","BK0239","BK0070","BK0188","BK0077"],"gpt_icon":0},{"id":"1125763108","title":"翰宇药业称计划通过股份私募筹集最多9.68亿元资金用于项目投资和补充资本","url":"https://stock-news.laohu8.com/highlight/detail?id=1125763108","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125763108?lang=zh_cn&edition=full","pubTime":"2025-09-25 19:35","pubTimestamp":1758800114,"startTime":"0","endTime":"0","summary":"翰宇药业称计划通过股份私募筹集最多9.68亿元资金用于项目投资和补充资本","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0239","300199","BK0070","BK0188","BK0077"],"gpt_icon":0},{"id":"2562426944","title":"股市必读：翰宇药业(300199)股东户数6.3万户，较上期增加9.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562426944","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562426944?lang=zh_cn&edition=full","pubTime":"2025-08-25 00:27","pubTimestamp":1756052834,"startTime":"0","endTime":"0","summary":"截至2025年8月22日收盘，翰宇药业报收于28.32元，下跌5.44%，换手率17.62%，成交量131.38万手，成交额37.35亿元。公司公告汇总：翰宇药业的醋酸阿托西班注射液获得越南药品上市许可，批件有效期至2030年7月17日。股本股东变化翰宇药业近日披露，截至2025年6月30日，公司股东户数为6.3万户，较3月31日增加5701户，增幅为9.95%。此外，翰宇药业还发布了2025年半年度非经营性资金占用及其他关联资金往来情况汇总表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082500000377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300199","BK0070","BK0188","BK0077"],"gpt_icon":0},{"id":"2561285491","title":"翰宇药业（300199）2025年中报简析：营收净利润同比双双增长，短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2561285491","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561285491?lang=zh_cn&edition=full","pubTime":"2025-08-23 06:16","pubTimestamp":1755900983,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期翰宇药业发布2025年中报。截至本报告期末，公司营业总收入5.49亿元，同比上升114.86%，归母净利润1.45亿元，同比上升1504.3%。按单季度数据看，第二季度营业总收入2.39亿元，同比上升127.07%，第二季度归母净利润7560.02万元，同比上升1919.66%。本报告期翰宇药业短期债务压力上升，流动比率达0.48。应收款项变动幅度为39.22%,原因:本报告期营业收入增加。营业成本变动幅度为102.06%,原因:本报告期国际制剂业务增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082300006640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2561474090","title":"翰宇药业披露4笔对外担保，被担保公司2家","url":"https://stock-news.laohu8.com/highlight/detail?id=2561474090","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561474090?lang=zh_cn&edition=full","pubTime":"2025-08-22 20:16","pubTimestamp":1755864960,"startTime":"0","endTime":"0","summary":"翰宇药业8月21日披露4笔对外担保，被担保公司2家。对外担保明细如下表：数据来源：天眼查APP \n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-08-22/doc-infmwmua5423268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0239","300199","BK0070","BK0188","BK0077"],"gpt_icon":0},{"id":"2561822465","title":"图解翰宇药业中报：第二季度单季净利润同比增长1919.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561822465","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561822465?lang=zh_cn&edition=full","pubTime":"2025-08-21 17:46","pubTimestamp":1755769588,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业2025年中报显示，公司主营收入5.49亿元，同比上升114.86%；归母净利润1.45亿元，同比上升1504.3%；扣非净利润1.23亿元，同比上升306.59%；其中2025年第二季度，公司单季度主营收入2.39亿元，同比上升127.07%；单季度归母净利润7560.02万元，同比上升1919.66%；单季度扣非净利润5783.04万元，同比上升232.49%；负债率78.02%，投资收益93.7万元，财务费用5206.13万元，毛利率62.46%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100030165.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2561688994","title":"翰宇药业最新公告：醋酸阿托西班注射液获得越南药品上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2561688994","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561688994?lang=zh_cn&edition=full","pubTime":"2025-08-21 17:00","pubTimestamp":1755766830,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，公司收到越南卫生部药品管理局下发的《药品注册证书》，公司产品“醋酸阿托西班注射液”获得越南的上市许可。该药品适用于有早产指征的妊娠妇女，用于推迟即将出现的早产，临床效果好，副作用小。该药品的上市许可将进一步丰富公司海外产品管线，拓宽公司海外市场，公司将积极推动该药品在海外市场的销售，提高公司的国际品牌影响力和综合竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082100028163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300199","BK0188","BK0239","BK0077","BK0028"],"gpt_icon":0},{"id":"2560178983","title":"翰宇药业与中国科学院过程工程研究所达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2560178983","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560178983?lang=zh_cn&edition=full","pubTime":"2025-08-20 15:41","pubTimestamp":1755675660,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ （来源：界面新闻）8月20日，深圳翰宇药业股份有限公司与中国科学院过程工程研究所正式签署战略合作协议，联合打造“多肽高端缓释制剂产业转化创新联合体”。双方将围绕多肽高端缓释制剂的“产—学—研—用”全链条开展深度合作，同时将以翰宇药业在研减重创新药HY3003为载体，运用多肽缓释技术，聚焦攻克GLP-1类药物在临床应用中的给药频率、胃肠道不良反应、低温运输及储存等问题。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-08-20/doc-infmrhsc1778800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0077","BK0070","BK0239","BK0028","BK0188","300199"],"gpt_icon":0},{"id":"2560115232","title":"翰宇药业股价下跌2.17% 与三生蔓迪签署减重药物商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2560115232","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560115232?lang=zh_cn&edition=full","pubTime":"2025-08-20 00:15","pubTimestamp":1755620128,"startTime":"0","endTime":"0","summary":"翰宇药业8月19日股价报29.26元，较前一交易日下跌0.65元，跌幅2.17%。当日开盘价为29.83元，最高触及30.67元，最低下探至28.58元，成交量为157.02万手，成交金额达46.36亿元。8月19日，翰宇药业与浙江三生蔓迪药业签署了《司美格鲁肽注射液委托生产和供应协议》，标志着双方在减重治疗领域的合作进入商业化落地阶段。该药物已完成三期临床试验全部受试者入组，目前处于2.4mg最高剂量稳定给药阶段。近五个交易日累计净流出3.42亿元，占流通市值的1.66%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/20001552549833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK0070","BK0077","BK0028","300199","BK0239"],"gpt_icon":0},{"id":"2560195809","title":"翰宇药业最新公告：与三生蔓迪签署司美格鲁肽注射液合作协议补充协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2560195809","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560195809?lang=zh_cn&edition=full","pubTime":"2025-08-19 19:19","pubTimestamp":1755602384,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，鉴于公司美格鲁肽注射液（减重适应症）国内临床试验已按照研究方案进行，正处于III期临床试验阶段，现已完成三期临床全部受试者入组，且进入了稳定给药期。为提前明确产品获批上市后的生产、供应等事宜，近日，依据原《司美格鲁肽注射液合作协议》的约定，公司与三生蔓迪签署了《委托生产和供应协议》、《药品委托生产质量协议》和《司美格鲁肽注射液合作协议之补充协议一》。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081900034889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300199","BK0028","BK0070","BK0239","BK0077"],"gpt_icon":0},{"id":"2559152915","title":"翰宇药业最新公告：副总裁张宝乐因个人原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2559152915","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559152915?lang=zh_cn&edition=full","pubTime":"2025-08-15 18:00","pubTimestamp":1755252048,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，公司副总裁张宝乐因个人原因申请辞去公司副总裁一职，其辞职报告自送达公司董事会之日起生效。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081500034810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0239","BK0188","BK0070","BK0077","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765110514782,"stockEarnings":[{"period":"1week","weight":0.0283},{"period":"1month","weight":-0.1123},{"period":"3month","weight":-0.2419},{"period":"6month","weight":0.2779},{"period":"1year","weight":0.4835},{"period":"ytd","weight":0.4663}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"110118人(较上一季度增加74.86%)","perCapita":"6771股","listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","registeredCapital":"88324万元","survey":" 深圳翰宇药业股份有限公司的主营业务是多肽药物研发、生产和销售。公司的主要产品是多肽制剂、多肽原料药、小核酸、CDMO/CMO。公司共获得国内专利授权298件，其中发明专利291件；翰宇药业（武汉）获得国内专利授权18件；成纪药业共获得国内专利授权115件。","listedPrice":30.19},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}